Results 51 to 60 of about 68,610 (290)

Tailored Porous Bimetallic Nanozyme Platform for Full‐Cycle Therapeutics of Intestinal Ischemia/Reperfusion

Advanced Science, EarlyView.
ABSTRACT Intestinal ischemia/reperfusion (I/R) injury presents a biphasic pathology: an acute oxidative‐inflammatory phase leading to organ failure, and a recovery phase marked by mucosal dysfunction and bacterial translocation. The developed MPB@TA‐Cu‐Ma nanocomposite functions as a dual‐phase therapeutic platform with significant efficacy. It rapidly
Chenghao Qiu, Wenjing Xian, Mengxue Wang, Guozhi Zhao, Yanhuo Zhang, Zhiyu Zhou, Bo Sheng, Zhuo Zhen, Xie Liu, Shouwen Diao, Mengwei Tu, Chen Qiu, Huixian Wang, Jianbo Zhang, Peng Zhu, Tong Li   +15 more
wiley   +1 more source

Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine

Pharmaceutics
Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents.
Mohamed El-Tanani, Shakta Mani Satyam, Syed Arman Rabbani, Yahia El-Tanani, Alaa A. A. Aljabali, Ibrahim Al Faouri, Abdul Rehman   +6 more
doaj   +1 more source

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study

Orphanet Journal of Rare Diseases, 2019
Background Orphan medicinal products (OMPs) are intended for the diagnosis, prevention, management or treatment of rare diseases (RDs). Each RD affects only a small fraction of the population, and therefore, historically, industry hesitated to undertake ...
Mohua Chakraborty Choudhury, Gayatri Saberwal   +1 more
doaj   +1 more source

MultiMetEval: comparative and multi-objective analysis of genome-scale metabolic models [PDF]

, 2012
Comparative metabolic modelling is emerging as a novel field, supported by the development of reliable and standardized approaches for constructing genome-scale metabolic models in high throughput.
A Freitag, A Gevorgyan, A Mithani, Albert Gevorgyan, AM Feist, AM Feist, AM Feist, Andrzej M. Kierzek, AP Burgard, BA Pfeifer, CS Henry, D Nagrath, DC Alexander, DC Stevens, EM Paradise, Eriko Takano, FC Lee, H Ikeda, I Thiele, J Gonzalez-Lergier, J Romero, J Schellenberger, JD Orth, JL Adrio, JP Brooks, JS Edwards, K Nieselt, K Yanai, LM Blank, M DeJongh, M Durot, M Kanehisa, M Latendresse, MA Fischbach, MA Oberhardt, MA Oberhardt, MA Oberhardt, Marnix H. Medema, MH Medema, MH Medema, MH Medema, MH Medema, MT Alam, MT Alam, MW Covert, N Scherr, ND Price, ND Price, NE Lewis, Piotr Zakrzewski, PR Ives, R Breitling, R Schuetz, Rainer Breitling, SA Becker, SD Bentley, Stephen S. Fong, TD Vo, TY Kim, XQ Zhao   +59 more
core   +6 more sources

Cancer‐Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT‐ANGPTL4 Axis

Advanced Science, EarlyView.
ABSTRACT Background & Aims: Cancer‐associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N‐methyltransferase (NNMT) in CAFs. Approach & Results: High NNMT expression in CAF tissues was confirmed by western blotting and
Shounan Lu, Shanjia Ke, Hongjun Yu, Zhanzhi Meng, Miaoyu Bai, Yanan Xu, Hui Zhu, Jinwen Yang, Baolin Qian, Bing Yin, Chaoqun Wang, Zhigang Feng, Zhongyu Li, Yongzhi Zhou, Zihao Li, Xinglong Li, Yongliang Hua, Yao Fu, Wei Tang, Yaohua Wu, Yong Ma   +20 more
wiley   +1 more source

Venture philanthropy in rare disease therapy

Rare
Purpose: Rare diseases affect ∼350 million people globally, yet 94 % of those affected lack effective treatments due to funding gaps and high R&D costs.
JA Levine
doaj   +1 more source

The outcome of more than 3 decades of orphan drug development in alpha-1-antitypsin deficiency – a cross sectional analysis of the FDA Orphan Drug Product designation database

, 2022
Abstract Introduction Alpha-1 antitrypsin deficiency (AATD, OMIM #613490) is a rare metabolic disorder affecting lungs and liver. The purpose of this study is to assess the impact of the US orphan drug act on AATD by providing a quantitative clinical-regulatory insight into the status of FDA orphan drug approvals and designations for compounds ...
Franziska C Trudzinski, Maria Ada Presotto, Emanuel Buck, Felix J. Herth, Markus Ries   +4 more
openaire   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine

Antioxidants
There is an urgent need for new approaches and strategies for the introduction of antioxidant drugs in medicine. Despite hundreds of clinical trials with potential antioxidants, no antioxidant drugs have so far been developed for clinical use; this is ...
George J. Kontoghiorghes
doaj   +1 more source